The AUCs of the post-treatment T1 and ΔADC values in predicting immunotherapy efficacy were 0.871 and 0.886, respectively.<h4>Conclusion</h4>T1 mapping and IVIM quantitative parameters may reflect potential trends in predicting PD-L1 expression, have certain value in monitoring the dynamic changes during immunotherapy in advanced lung cancer, and are expected to provide meaningful imaging biomarkers for individualized immunotherapy decision-making. The gene discussed is CD274; the disease is lung cancer.